翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年9月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) 01672 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | 已發行股份總數 | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Major Events - Different Group (06090) has a public offering with a subscription rate of 3317.47 times the upper limit price [1] - Botai Che Lian (02889) plans to globally offer 10.4369 million H-shares from September 22 to September 25 [1] - Changhong Jiahua (03991) received a privatization offer from Changhong Group at a premium of approximately 32.93%, with resumption of trading on September 23 [1] - Huajian Medical (01931) signed a strategic cooperation agreement with Chuangsheng Group-B (06628) involving the tokenization of a $1.5 billion innovative drug pipeline asset [1] - Gilead Sciences-B (01672) reported that ASC47 combined with Semaglutide showed a weight loss effect improvement of up to 56.2% compared to Semaglutide alone in obese subjects [1] - Fosen Pharmaceutical (01652) plans to sell all equity of Henan Fosen Smart Energy Technology for 73 million yuan [1] - Maiyue Technology (02501) entered into strategic cooperation agreements with NetEase Youdao and Ferry International [1] - Zhongchuang Zhiling (00564) intends to invest 270 million yuan to establish Yaxinke Thermal Management Technology (Yizheng) Co., Ltd. to enhance market competitiveness in automotive thermal management systems [1] - Garmin Group Holdings (01271) plans to sell a portfolio of four data center projects for 5.25 billion HKD [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 862,000 shares for 550 million HKD on September 22 [1] - Standard Chartered Group (02888) repurchased 517,100 shares for 7.3877 million GBP on September 19 [1] - Midea Group (00300) repurchased 3.415 million A-shares for 250 million yuan on September 22 [1] - Anta Sports (02020) repurchased 2.12 million shares for 199 million HKD on September 22 [1] - Kuaishou-W (01024) repurchased 1 million shares for 73.7998 million HKD on September 22 [1] - Heng Rui Pharmaceutical (01276) repurchased 656,000 A-shares for 45.7493 million yuan on September 19 [1] - Shenzhen Expressway Company (00548) received an increase of 25.38 million H-shares from shareholder Yunsong Capital [1]

Group 1 - The pharmaceutical stocks have generally risen, with notable increases in companies such as WuXi AppTec (6.82% increase), Innovent Biologics (5.72% increase), and WuXi Biologics (3.86% increase) [1] - The National Healthcare Security Administration has released the 11th batch of centralized procurement documents for drugs, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The optimization of price control benchmarks in the procurement process indicates a shift away from simply selecting the lowest bid, reflecting a proactive approach by the healthcare authority to improve the domestic market [1] Group 2 - Guojin Securities expresses strong confidence in a reversal trend for the pharmaceutical sector in 2025, highlighting innovative drugs and the recovery of left-behind sectors as significant investment opportunities [2] - The upward trend in the innovative drug industry remains intact, with multinational corporations facing patent cliffs and likely to continue using business development strategies to fill revenue gaps [2] - Dongwu Securities notes that the easing interest rate environment is expected to enhance the prosperity of the innovative industry chain, benefiting upstream biotech and CXO sectors [2]

每经AI快讯，9月22日，港股医药股多数上扬。截至发稿，药明合联(02268.HK)涨6.82%，报75.2港元； 诺诚健华(09969.HK)涨5.72%，报17.38港元；药明生物(02269.HK)涨3.86%，报39.24港元；歌礼制药- B(01672.HK)涨3.09%，报11.01港元；恒瑞医药(01276.HK)涨2.74%，报90港元。 ...

Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 8%, reaching HKD 11.57 with a trading volume of HKD 23.73 million, following the announcement of significant clinical trial results for its weight loss drug ASC47 combined with semaglutide [1] Group 1: Clinical Trial Results - Gilead announced that in a study conducted on obese participants (BMI ≥ 30 kg/m²), the combination of ASC47 and semaglutide showed a weight loss effect that was 56.2% greater compared to the placebo combined with semaglutide [1] Group 2: Future Research Implications - The CEO of Gilead, Wu Jinzi, stated that this research provides important concept validation data, which will serve as a critical basis for the design of subsequent Phase IIb combination therapy studies targeting various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 8%, reaching HKD 11.57, with a trading volume of HKD 23.73 million, following the announcement of significant weight loss results from its candidate drug ASC47 in combination with semaglutide [1] Group 1: Company Announcement - Gilead Sciences announced that, on day 29, the weight loss effect of ASC47 combined with semaglutide in obese subjects (BMI ≥ 30 kg/m²) was enhanced by up to 56.2% compared to the placebo combined with semaglutide [1] - The founder, chairman, and CEO of Gilead Sciences, Wu Jinzi, stated that this study provides important proof-of-concept data, which will serve as a critical basis for the design of subsequent Phase IIb combination therapy studies for various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]

"作为首项在肥胖受试者中评估脂肪靶向THRβ激动剂与肠促胰素药物联用的研究，我们非常欣喜地看到 脂肪靶向THRβ激动剂ASC47联用肠促胰素治疗产生了显著的减重协同疗效，减重效果相对提升高达 56.2%，并大幅改善了胃肠道耐受性，"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，"这项 研究提供了重要的概念验证数据，将为我们后续的包括肥胖症和代谢相关脂肪性肝炎(MASH)等多种代 谢疾病的IIb期联合用药研究设计提供关键依据。" ASC47-103研究(NCT06972992)是一项在美国开展的随机、双盲、安慰剂对照的研究，旨在评估超长效 皮下注射ASC47单次给药与司美格鲁肽(0.5毫克，每周一次，给药四次)联用对比等量(volume-matched) 安慰剂与司美格鲁肽(0.5毫克，每周一次，给药四次)联用在肥胖受试者中的安全性、耐受性及疗效。治 疗期为4周，随访期为6周。该研究在美国开展，共入组了28例肥胖受试者。研究目标包括安全性、耐受 性、药代动力学、ASC47三种不同剂量单次给药(10毫克、30毫克和60毫克)与司美格鲁肽(0.5毫克，每 周一次，给药四次)联用的减重疗效评估。由于治疗周期短(2 ...

Group 1 - The core finding of the study indicates that the combination of ASC47 and semaglutide resulted in a weight loss effect that was enhanced by up to 56.2% compared to the placebo and semaglutide combination [1][2] - The ASC47-103 study was a randomized, double-blind, placebo-controlled trial conducted in the United States, involving 28 obese participants with a body mass index (BMI) of 30 kg/m² or higher [1] - The study aimed to evaluate the safety, tolerability, and efficacy of a single dose of ASC47 in three different dosages (10 mg, 30 mg, and 60 mg) in conjunction with semaglutide, with a treatment period of 4 weeks and a follow-up period of 6 weeks [1] Group 2 - The CEO of the company expressed satisfaction with the significant synergistic weight loss effects observed from the combination of the fat-targeting THRβ agonist ASC47 and the incretin therapy, which also greatly improved gastrointestinal tolerability [2] - This study serves as an important proof-of-concept and will provide critical data for the design of subsequent Phase IIb combination therapy studies targeting obesity and metabolic-associated fatty liver disease (MASH) [2]

Core Viewpoint - The study indicates that the combination of ASC47 and semaglutide significantly enhances weight loss in obese subjects compared to semaglutide alone, with a relative improvement of up to 56.2% [1] Group 1: Drug Efficacy - ASC47, a fat-targeting THRβ agonist, when combined with the gut hormone drug semaglutide, shows a significant synergistic effect on weight loss in obese participants (BMI ≥ 30 kg/m²) [1] - The combination therapy not only improves weight loss outcomes but also significantly enhances gastrointestinal tolerability [1] Group 2: Future Research Implications - The results provide important concept validation data that will inform the design of subsequent Phase IIb combination therapy studies for various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 歌禮宣布ASC47聯合司美格魯肽在肥胖受試者中 較司美格魯肽單藥減重效果相對提升高達56.2% 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣布，在第29天時，減重不減肌候選藥物 ASC47與司美格魯肽聯用在肥胖受試者（體重指數≥30 kg/m²）中較安慰劑與司美格 魯肽聯用（司美格魯肽單藥）減重效果相對提升高達56.2%。 ASC47-103研究(NCT06972992)是一項在美國開展的隨機、雙盲、安慰劑對照的 研究，旨在評估超長效皮下注射ASC47單次給藥與司美格魯肽（0.5毫克，每周一 次，給藥四次）聯用對比等量(volume-ma ...